Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma.

NCT01987505 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01987505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01987505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
November 11, 2013
Completion date
April 11, 2017
Enrollment
140 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non hodgkin